Chang‐Ki Min

2.3k total citations
43 papers, 698 citations indexed

About

Chang‐Ki Min is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Chang‐Ki Min has authored 43 papers receiving a total of 698 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 18 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Chang‐Ki Min's work include Multiple Myeloma Research and Treatments (23 papers), Hematopoietic Stem Cell Transplantation (16 papers) and Peptidase Inhibition and Analysis (10 papers). Chang‐Ki Min is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Hematopoietic Stem Cell Transplantation (16 papers) and Peptidase Inhibition and Analysis (10 papers). Chang‐Ki Min collaborates with scholars based in South Korea, United States and Ethiopia. Chang‐Ki Min's co-authors include Shawn G. Clouthier, James L.M. Ferrara, Seok Lee, Ulrich Duffner, Hong Wang, Gilbert S. Omenn, David E. Misek, Rong Zhao, Samir Hanash and Eun Young Choi and has published in prestigious journals such as Nature Communications, Blood and Cancer.

In The Last Decade

Chang‐Ki Min

41 papers receiving 683 citations

Peers

Countries citing papers authored by Chang‐Ki Min

Since Specialization

Citations

This map shows the geographic impact of Chang‐Ki Min's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chang‐Ki Min with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chang‐Ki Min more than expected).

Fields of papers citing papers by Chang‐Ki Min

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chang‐Ki Min. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chang‐Ki Min. The network helps show where Chang‐Ki Min may publish in the future.

Co-authorship network of co-authors of Chang‐Ki Min

This figure shows the co-authorship network connecting the top 25 collaborators of Chang‐Ki Min. A scholar is included among the top collaborators of Chang‐Ki Min based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chang‐Ki Min. Chang‐Ki Min is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea 2025 ·Cancer Research and Treatment ·Jun Ho Yi, Jae Hoon Lee, Sung‐Hoon Jung, Mi Ji Lee, Ji Yun Lee, Kihyun Kım, (unknown), Chang‐Ki Min, Yoon Seok Choi, (unknown), Ho‐Young Yhim, Dok Hyun Yoon	0
2	Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party (KMMWP-174 study) 2025 ·Haematologica ·(unknown), Seung Pil Jung, (unknown), (unknown), Jin Seok Kim, (unknown), Seong Kyu Park, Hyo Jung Kim, Gyeong‐Won Lee, Young Hoon Park, (unknown), Jeong‐Ah Kim, Min Kyoung Kim, Yundeok Kim, Ho‐Jin Shin, Ho Sup Lee, Jihyun Kwon, Chang‐Ki Min	0
3	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR 2019 ·Clinical Lymphoma Myeloma & Leukemia ·María‐Victoria Mateos, Pieter Sonneveld, Vânia Hungria, Ajay K. Nooka, Jane Estell, Wolney Barreto, Paolo Corradini, Chang‐Ki Min, Eva Medvedova, Katja Weisel, Christopher Chiu, Jordan M. Schecter, Himal Amin, Xiang Qin, Jon Ukropec, Rachel Kobos, Andrew Spencer	93
4	CD1d is a novel cell-surface marker for human monocytic myeloid-derived suppressor cells with T cell suppression activity in peripheral blood after allogeneic hematopoietic stem cell transplantation 2017 ·Biochemical and Biophysical Research Communications ·(unknown), (unknown), (unknown), Dong-Mi Shin, Eun Young Choi, Chang‐Ki Min, (unknown)	11
5	Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation 2017 ·Biology of Blood and Marrow Transplantation ·Sung‐Eun Lee, (unknown), Tae Woo Kim, Young‐Woo Jeon, (unknown), Byung-Sik Cho, Ki‐Seong Eom, Yoo‐Jin Kim, Hee‐Je Kim, Seok Lee, Seok‐Goo Cho, Dong‐Wook Kim, Jong Wook Lee, (unknown), Dong-Mi Shin, Eun Young Choi, Chang‐Ki Min	28
6	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea 2016 ·Annals of Hematology ·(unknown), Ho Sup Lee, Chang‐Ki Min, Je‐Jung Lee, Kihyun Kım, Seok Jin Kim, Dok Hyun Yoon, Hyeon‐Seok Eom, Hyewon Lee, Won Sik Lee, Ho‐Jin Shin, Ji Hyun Lee, Yong Park, Jae‐Cheol Jo, Young Rok, Yeung‐Chul Mun, Mark Hong Lee	3
7	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea 2015 ·Blood Research ·Hyo Jung Kim, Sung‐Soo Yoon, Hyeon Seok Eom, Kihyun Kım, Jin Seok Kim, Je‐Jung Lee, Soo‐Mee Bang, Chang‐Ki Min, Joon Seong Park, Jae Hoon Lee, (unknown)	3
8	Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy 2015 ·Journal of Clinical Virology ·Ji‐Won Kim, Chang‐Ki Min, Yeung‐Chul Mun, Yong Park, Byung Soo Kim, (unknown), Youngil Koh, (unknown), Pyoeng Gyun Choe, Wan Beom Park, Inho Kim	19
9	Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF 2015 ·Leukemia & lymphoma ·Ji Eun Jang, June‐Won Cheong, Soo‐Jeong Kim, Hyunsoo Cho, Cheolwon Suh, Hyewon Lee, Hyeon‐Seok Eom, Ho‐Young Yhim, Won Sik Lee, Chang‐Ki Min, Jae Hoon Lee, Joon Seong Park, Jin Seok Kim	7
10	Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation 2015 ·Molecules and Cells ·(unknown), (unknown), Sung‐Eun Lee, Gyeongsin Park, Eun Young Choi, Chang‐Ki Min	7
11	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea 2014 ·BioMed Research International ·(unknown), Kihyun Kım, Dok Hyun Yoon, Jin Seok Kim, Soo‐Mee Bang, Jeong‐Ok Lee, Hyeon Seok Eom, Hyewon Lee, Inho Kim, Won Sik Lee, Sung Hwa Bae, Se Hyung Kim, Mark Hong Lee, Young Rok, Jae Hoon Lee, Junshik Hong, Ho‐Jin Shin, Ji Hyun Lee, Yeung‐Chul Mun, Chang‐Ki Min	3
12	A paradoxical pattern of indoleamine 2,3-dioxygenase expression in the colon tissues of patients with acute graft-versus-host disease 2014 ·Experimental Hematology ·Gyeongsin Park, Yeong Jin Choi, Sung‐Eun Lee, (unknown), Chulbom Lee, Eun Young Choi, Chang‐Ki Min	6
13	The role of regulatory T cells during the attenuation of graft-versus-leukemia activity following donor leukocyte infusion in mice 2011 ·Leukemia Research ·(unknown), (unknown), Byung-Sik Cho, Yoo‐Jin Kim, Nack‐Gyun Chung, Dae Chul Jeong, Hyewon Youn, Chulbom Lee, Eun Young Choi, Chang‐Ki Min	4
14	The influence of pretransplantation conditioning on graft-vs.-leukemia effect in mice 2011 ·Experimental Hematology ·(unknown), (unknown), Hyewon Youn, Eun Young Choi, Chang‐Ki Min	7
15	Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients 2010 ·Annals of Oncology ·(unknown), Cheolwon Suh, Daniel Lee, Chang‐Ki Min, Seung Ju Kim, Kihyun Kım, Joon Ho Moon, Sung‐Soo Yoon, (unknown), Hye Jin Kang, (unknown), Chul Won Choi, Hyeon‐Seok Eom, Jae‐Yong Kwak, (unknown), Yeung‐Chul Mun, Soo‐Mee Bang, (unknown), Ho‐Jin Shin, (unknown)	25
16	Bortezomib in Combination with Conventional Chemotherapeutic Agents for Multiple Myeloma Compared with Bortezomib Alone 2007 ·Japanese Journal of Clinical Oncology ·Chang‐Ki Min, (unknown), Ki‐Seong Eom, (unknown), Jae Wook Lee, (unknown), (unknown), Myungshin Kim, Jihyang Lim, Young-Wook Kim, Kyungja Han	17
17	Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro‐inflammatory cytokines 2006 ·European Journal Of Haematology ·Chang‐Ki Min, Seok Lee, Yoo‐Jin Kim, Ki‐Seong Eom, Jong‐Wook Lee, Woo‐Sung Min, (unknown), Chul‐Soo Cho, Gyeongsin Park	35
18	A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma 2006 ·International Journal of Hematology ·Soo‐Mee Bang, Jae Seung Lee, Sung‐Soo Yoon, Seonyang Park, Chang‐Ki Min, (unknown), Cheolwon Suh, Sang Kyun Sohn, Yoo Hong Min, Je‐Jung Lee, Kihyun Kım, Chu‐Myong Seong, (unknown), Kyung Cho, Deog‐Yeon Jo, Kyung Min Lee, (unknown), Chul Kim	28
19	Intact-protein-based High-resolution Three-dimensional Quantitative Analysis System for Proteome Profiling of Biological Fluids 2005 ·Molecular & Cellular Proteomics ·Hong Wang, Shawn G. Clouthier, (unknown), David E. Misek, Ulrich Duffner, Chang‐Ki Min, Rong Zhao, John Tra, Gilbert S. Omenn, James L.M. Ferrara, Samir Hanash	113
20	Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B‐lineage acute lymphoblastic leukaemia in first or second remission 2002 ·British Journal of Haematology ·Seok Lee, Dongwook Kim, Yoo‐Jin Kim, (unknown), Chang‐Ki Min, Jong‐Wook Lee, (unknown), (unknown)	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact